Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of an intravenous antibiotic vial and sterile hospital laboratory setup, reflecting Wockhardt’s Zaynich FDA approval and India’s growing role in antimicrobial resistance innovation.
Pharma & Biotech

Can Zaynich help Wockhardt turn Indian antibiotic innovation into a global commercial platform?

Find out how Wockhardt’s Zaynich FDA approval could reshape Indian pharma innovation and the fight against drug-resistant infections.

Read More
Representative image of pharmaceutical quality control and drug manufacturing, reflecting Concord Biotech’s United States Food and Drug Administration approval for Mycophenolate Mofetil oral suspension and the market focus on its transplant immunosuppressant portfolio.
Pharma & Biotech

Can Mycophenolate Mofetil approval strengthen Concord Biotech’s United States generics strategy?

Find out how Concord Biotech’s FDA approval for Mycophenolate Mofetil could reshape its transplant generics strategy.

Read More
Representative image of a modern biologics manufacturing facility. Aurobindo Pharma’s TheraNym Biologics launch highlights India’s push into high-capacity CDMO infrastructure, advanced bioreactor manufacturing, and global biologics outsourcing.
Pharma & Biotech

Aurobindo Pharma launches TheraNym as MSD anchor deal strengthens biologics CDMO push

Find out how Aurobindo Pharma’s TheraNym launch could reshape India’s biologics CDMO ambitions and investor sentiment.

Read More
Pharma & Biotech

Why Gilead Sciences’ Livdelzi data could reshape treatment goals in primary biliary cholangitis

Find out how Gilead Sciences’ Livdelzi trial data could reshape PBC treatment goals and strengthen the case for ALP normalization.

Read More
Representative image of immunology research and clinical trial analysis, reflecting Johnson & Johnson’s growing nipocalimab strategy in lupus and Sjögren’s disease.
Pharma & Biotech

Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout

See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!

Read More
Representative image: Biomedical researchers analyse immune-cell data in a laboratory setting, reflecting the scientific focus behind Antengene’s ATG-207 preclinical autoimmune therapy program and its CD3 and TGF-beta fusion approach.
Pharma & Biotech

Antengene brings first ATG-207 preclinical data to EULAR 2026 as autoimmune focus deepens

Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.

Read More
Representative image: An oncologist reviews lung scan images in a modern cancer care setting, reflecting Amgen’s EU approval for Imdylltra in relapsed extensive-stage small cell lung cancer.
Pharma & Biotech

Why Amgen’s Imdylltra EU approval could reshape second-line small cell lung cancer treatment

Find out how Amgen’s Imdylltra EU approval could change relapsed small cell lung cancer treatment across Europe.

Read More
Representative image of scientists reviewing oncology research data in a modern biopharma laboratory, reflecting Pfizer and Innovent Biologics’ $10.5 billion collaboration and the growing race to develop antibody-drug conjugates and multispecific cancer therapies.
Pharma & Biotech

Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?

Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.

Read More
Representative image of an oncologist reviewing lung cancer scans with a patient, reflecting Nuvalent’s neladalkib FDA Priority Review and the growing race to develop targeted therapies for ALK-positive non-small cell lung cancer.
Pharma & Biotech

Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves

Nuvalent’s neladalkib has FDA Priority Review in ALK-positive lung cancer. Find out why resistance and brain metastases drive the story.

Read More
Representative image of pharmaceutical executives and scientists reviewing drug discovery data in a modern research setting, reflecting Eli Lilly and Haisco Pharmaceutical’s multi-program collaboration and the growing role of China-originated innovation in global pharma licensing.
Pharma & Biotech

Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?

Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.

Read More